Literature DB >> 20595036

HTLV-I p30: a versatile protein modulating virus replication and pathogenesis.

Xue Tao Bai1, Hicham Hachem Baydoun, Christophe Nicot.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595036      PMCID: PMC2981346          DOI: 10.1016/j.mam.2010.05.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


× No keyword cloud information.
  26 in total

1.  In vivo production of Rof and Tof proteins of HTLV type 1: evidence from cytotoxic T lymphocytes.

Authors:  C Pique; M C Dokhelar
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

2.  Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I.

Authors:  I J Koralnik; A Gessain; M E Klotman; A Lo Monico; Z N Berneman; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  Human T-lymphotropic virus type 1 p30(II) regulates gene transcription by binding CREB binding protein/p300.

Authors:  W Zhang; J W Nisbet; B Albrecht; W Ding; F Kashanchi; J T Bartoe; M D Lairmore
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  The p12I, p13II, and p30II proteins encoded by human T-cell leukemia/lymphotropic virus type I open reading frames I and II are localized in three different cellular compartments.

Authors:  I J Koralnik; J Fullen; G Franchini
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

Review 5.  Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis.

Authors:  Björn Albrecht; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

6.  HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.

Authors:  Christophe Nicot; Miroslav Dundr; Julie M Johnson; Jake R Fullen; Norma Alonzo; Risaku Fukumoto; Gerald L Princler; David Derse; Tom Misteli; Genoveffa Franchini
Journal:  Nat Med       Date:  2004-01-18       Impact factor: 53.440

7.  Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator.

Authors:  Ihab Younis; Lyne Khair; Miroslav Dundr; Michael D Lairmore; Genoveffa Franchini; Patrick L Green
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV type I.

Authors:  V Ciminale; G N Pavlakis; D Derse; C P Cunningham; B K Felber
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.

Authors:  C Pique; A Ureta-Vidal; A Gessain; B Chancerel; O Gout; R Tamouza; F Agis; M C Dokhélar
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  Genome wide analysis of human genes transcriptionally and post-transcriptionally regulated by the HTLV-I protein p30.

Authors:  John M Taylor; Sofiane Ghorbel; Christophe Nicot
Journal:  BMC Genomics       Date:  2009-07-14       Impact factor: 3.969

View more
  12 in total

1.  Human T lymphotropic virus type 1 regulatory and accessory gene transcript expression and export are not rex dependent.

Authors:  Min Li; Priya Kannian; Han Yin; Matthew Kesic; Patrick L Green
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

2.  Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Authors:  Megan M Romeo; Bookyung Ko; Janice Kim; Rebecca Brady; Hayley C Heatley; Jeffrey He; Carolyn K Harrod; Braden Barnett; Lee Ratner; Michael D Lairmore; Ernest Martinez; Bernhard Lüscher; Craig N Robson; Marie Henriksson; Robert Harrod
Journal:  Virology       Date:  2015-01-05       Impact factor: 3.616

Review 3.  Cell cycle regulation during viral infection.

Authors:  Sumedha Bagga; Michael J Bouchard
Journal:  Methods Mol Biol       Date:  2014

4.  Discovery and characterization of auxiliary proteins encoded by type 3 simian T-cell lymphotropic viruses.

Authors:  Jocelyn Turpin; Chloé Journo; Nga Ling Ko; Flore Sinet; Alexandre Carpentier; Amandine Galioot; Dustin Edwards; Anne-Mieke Vandamme; Louis Gazzolo; Madeleine Duc Dodon; Antoine Gessain; Fatah Kashanchi; Ivan Balansard; Romain Lacoste; Renaud Mahieux
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

5.  HTLV-1 Rex: the courier of viral messages making use of the host vehicle.

Authors:  Kazumi Nakano; Toshiki Watanabe
Journal:  Front Microbiol       Date:  2012-09-06       Impact factor: 5.640

Review 6.  Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence.

Authors:  Dustin Edwards; Claudio Fenizia; Heather Gold; Maria Fernanda de Castro-Amarante; Cody Buchmann; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  Viruses       Date:  2011-06-17       Impact factor: 5.048

Review 7.  HTLV-1 and HTLV-2: highly similar viruses with distinct oncogenic properties.

Authors:  Vincenzo Ciminale; Francesca Rende; Umberto Bertazzoni; Maria G Romanelli
Journal:  Front Microbiol       Date:  2014-07-29       Impact factor: 5.640

Review 8.  HTLV-1 Rex Tunes the Cellular Environment Favorable for Viral Replication.

Authors:  Kazumi Nakano; Toshiki Watanabe
Journal:  Viruses       Date:  2016-02-24       Impact factor: 5.048

9.  Comparison of the Genetic Organization, Expression Strategies and Oncogenic Potential of HTLV-1 and HTLV-2.

Authors:  Francesca Rende; Ilaria Cavallari; Maria Grazia Romanelli; Erica Diani; Umberto Bertazzoni; Vincenzo Ciminale
Journal:  Leuk Res Treatment       Date:  2011-12-29

10.  Overview on HTLV-1 p12, p8, p30, p13: accomplices in persistent infection and viral pathogenesis.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  Front Microbiol       Date:  2012-12-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.